Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01989559 · ClinicalTrials.gov registry record · Phase 1
Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT01989559: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT01989559 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01989559, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This pilot clinical trial studies booster vaccination in preventing disease recurrence in previously vaccinated patients with melanoma that has been removed by surgery. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Giving booster vaccinations may make a stronger immune response and prevent or delay the recurrence of cancer.
Interventions
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL gp100:209-217(210M) Peptide Vaccine
- BIOLOGICAL HPV 16 E7:12-20 Peptide Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2002-10 |
| Est. Completion | 2013-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01989559
The ClinicalTrials.gov registry entry for NCT01989559 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01989559 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01989559 about?
NCT01989559 is a clinical study titled "Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery". This pilot clinical trial studies booster vaccination in preventing disease recurrence in previously vaccinated patients with melanoma that has been removed by surgery. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Giving booster vaccinations m...
What is the current status of trial NCT01989559?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2002-10. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01989559?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), gp100:209-217(210M) Peptide Vaccine (BIOLOGICAL), HPV 16 E7:12-20 Peptide Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01989559?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.